Xenium for cells: Mechanism of action studies with the STAMP worflow I CRO services

Xenium for cells with the STAMP workflow offers a powerful alternative to single-cell RNA sequencing. By combining cell phenotyping and gene expression analysis on the 10x Genomics Xenium platform, this approach delivers single-cell resolution, fast turnaround, and reduced costs. Unlike traditional scRNA-seq, the STAMP workflow does not require sequencing. Up to 16 samples can be processed in a single run, generating results within a week. Each spot captures more than 60,000 cells, making this method particularly relevant for studying rare cell populations and subtle immune shifts. This workflow provides high correlation with flow cytometry and bulk transcriptomics, ensuring robust and reproducible results. It allows detailed cell phenotyping combined with targeted gene expression analysis, enabling precise mechanism of action studies in complex models. Explicyte applies Xenium STAMP in both in vitro and ex vivo settings. For in vitro assays, it supports lead characterization and profiling in 2D and 3D cellular models. In vivo, it enables ex vivo analysis of PBMCs and tumor samples, particularly in mouse models, to characterize immune responses and drug mechanisms. The approach also extends to clinical research, where PBMCs from patient blood samples can be analyzed to reveal circulating biomarkers and immunotherapy response. A recent case study illustrates the potential of this workflow. Using the Xenium IO panel with STAMP, Explicyte profiled PBMCs stimulated with nivolumab. In just one week, over one million cells were analyzed with high-fidelity phenotyping and targeted gene expression readouts. The method not only aligned with flow cytometry and RNA-seq but also detected rare immune subsets affected by therapy. With over ten years of experience in immuno-oncology, Explicyte brings expertise in lead characterization, mechanism of action studies, and biomarker discovery. Our data science team specializes in spatial transcriptomics and advanced single-cell analytics, ensuring maximum value from every dataset. Alternative technologies such as flow cytometry, bulk RNA-seq, and 10x Chromium single-cell RNA-seq are also available to complement Xenium studies. Every project benefits from a personalized approach. A dedicated study director designs the experimental plan, guides the analytical strategy, and ensures that results align with your scientific objectives. Custom Xenium panels can be developed beyond the standard 5K panel, enabling tailored solutions for specific research questions. By leveraging the Xenium STAMP workflow, Explicyte delivers sequencing-free, single-cell transcriptomics that accelerate mechanism of action studies, biomarker discovery, and drug development.